Evaluation of inter- and intrafraction organ motion during intensity modulated radiation therapy (IMRT) for localized prostate cancer measured by a newly developed on-board image-guided system.

PURPOSE To investigate prostatic organ motion at both setup and intrafraction using an onboard image-guided system. An intrafraction field-based repositioning method also was evaluated. MATERIALS AND METHODS A dual fluoroscopy with amorphous-silicon flat panel (DFFP) system was used for the three-dimensional registration of implanted markers in the prostate of eight organ-confined cancer patients planned for treatment with intensity modulated radiation therapy (IMRT). Day-to-day motion errors were quantified and intrafraction displacements of more than +/-1 mm were corrected. RESULTS Among 214 fractions and 565 system views, day-to-day mean magnitude of marker discrepancy +/- standard deviation (SD) was 1.76 +/- 1.4 mm, 3.14 +/- 1.6 mm, and 3.78 +/- 2.4 mm in the right-left, cranial-caudal, and anterior-posterior directions, respectively. The intrafractional mean magnitude +/- SD of marker displacement was 0.45 +/- 0.7 mm, 1.08 +/- 1.38 mm and 1.45 +/- 1.70 mm in the right-left, cranial-caudal, and anterior-posterior directions, respectively. Intrafraction corrected sessions (84/214) showed a median (range) of motion of 0.1 mm (-1.2 to 0.7 mm), -0.2 mm (-2.1 to 1.1 mm), and -0.2 mm (-1.7 to 2.0 mm) in the right-left, cranial-caudal, and anterior-posterior directions, respectively. CONCLUSION Motion uncertainty can be considerably decreased with daily use of the DFFP system. Reduced intrafraction organ motion clearly endorsed the value of the repositioning approach, allowing a safer dose escalation protocol.